ClearPoint Neuro, Inc.
CLPT Healthcare Medical Devices
ClearPoint Neuro, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $37.0 million, up 17.8% from fiscal 2024. In the quarter to June 2026, revenue grew 18.1%, EPS fell 81.0%, free cash flow fell 173.5% and total debt rose 74.1%, each against the same quarter a year earlier. Revenue growth for five consecutive years.
Follow CLPT
ClearPoint Neuro, Inc. (CLPT) Altman Z-score
ClearPoint Neuro, Inc.'s Altman Z-score for fiscal 2025 is 0.44, in the distress zone (below 1.81).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2025 | 0.44 | (10.64) |
| FY2024 | 11.08 | 12.44 |
| FY2023 | −1.36 | (4.53) |
| FY2022 | 3.17 | (2.90) |
| FY2021 | 6.07 | 5.53 |
| FY2020 | 0.54 | 8.29 |
| FY2019 | −7.74 | 10.27 |
| FY2018 | −18.02 | (9.17) |
| FY2017 | −8.85 | 10.28 |
| FY2016 | −19.13 | (6.09) |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.54 | — | 0.65 | |
| Retained earnings / total assets | (2.22) | — | −3.11 | |
| EBIT / total assets | (0.25) | — | −0.82 | |
| Market value of equity / total liabilities | 5.56 | — | 3.33 | |
| Sales / total assets | 0.38 | — | 0.38 | |
| Altman Z-score | Distress zone | 0.44 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Distress zone | −4.93 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| CV CapsoVision, Inc. compare | 17.0× |
| INFU InfuSystems Holdings, Inc. compare | 3.7× |
| CLPT ClearPoint Neuro, Inc. | 0.4× |
| QSI Quantum-Si Incorporated compare | 0.4× |
| TMCI Treace Medical Concepts, Inc. compare | −0.1× |
| CATX Perspective Therapeutics, Inc. compare | −0.6× |
| LAB Standard BioTools Inc. compare | −0.8× |
| TLSI TriSalus Life Sciences, Inc. compare | −11.3× |
| RCEL Avita Medical Inc. compare | −12.0× |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets